## Elena Veronesi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/604007/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Microscopic and chemical characterization of PVC tube used for dialysis lines: A new approach. International Journal of Artificial Organs, 2021, 44, 75-84.	0.7	0
2	Testing Surgical Face Masks in an Emergency Context: The Experience of Italian Laboratories during the COVID-19 Pandemic Crisis. International Journal of Environmental Research and Public Health, 2021, 18, 1462.	1.2	17
3	Microfragmented adipose tissue is associated with improved ex vivo performance linked to HOXB7 and b-FGF expression. Stem Cell Research and Therapy, 2021, 12, 481.	2.4	5
4	TRAIL receptors are expressed in both malignant and stromal cells in pancreatic ductal adenocarcinoma. American Journal of Cancer Research, 2021, 11, 4500-4514.	1.4	0
5	Early efficacy evaluation of mesenchymal stromal cells (MSC) combined to biomaterials to treat long bone non-unions. Injury, 2020, 51, S63-S73.	0.7	32
6	A new bioactive glass with extremely high crystallization temperature and outstanding biological performance. Materials Science and Engineering C, 2020, 110, 110699.	3.8	22
7	On the in Vitro Biocompatibility Testing of Bioactive Glasses. Materials, 2020, 13, 1816.	1.3	14
8	Inducible Caspase9-mediated suicide gene for MSC-based cancer gene therapy. Cancer Gene Therapy, 2019, 26, 11-16.	2.2	45
9	Challenges in Clinical Development of Mesenchymal Stromal/Stem Cells: Concise Review. Stem Cells Translational Medicine, 2019, 8, 1135-1148.	1.6	182
10	Human Mesenchymal Stem Cell Combined with a New Strontium-Enriched Bioactive Glass: An ex-vivo Model for Bone Regeneration. Materials, 2019, 12, 3633.	1.3	25
11	Translation of a standardized manufacturing protocol for mesenchymal stromal cells: A systematic comparison of validation and manufacturing data. Cytotherapy, 2019, 21, 468-482.	0.3	33
12	A Novel 3D In Vitro Platform for Pre-Clinical Investigations in Drug Testing, Gene Therapy, and Immuno-oncology. Scientific Reports, 2019, 9, 7154.	1.6	50
13	Impact of HOXB7 overexpression on human adipose-derived mesenchymal progenitors. Stem Cell Research and Therapy, 2019, 10, 101.	2.4	16
14	Soluble TRAIL Armed Human MSC As Gene Therapy For Pancreatic Cancer. Scientific Reports, 2019, 9, 1788.	1.6	57
15	MSC-Delivered Soluble TRAIL and Paclitaxel as Novel Combinatory Treatment for Pancreatic Adenocarcinoma. Theranostics, 2019, 9, 436-448.	4.6	39
16	Feasibility and safety of treating non-unions in tibia, femur and humerus with autologous, expanded, bone marrow-derived mesenchymal stromal cells associated with biphasic calcium phosphate biomaterials in a multicentric, non-comparative trial. Biomaterials, 2019, 196, 100-108.	5.7	87
17	Label-free toxicology screening of primary human mesenchymal cells and iPS-derived neurons. PLoS ONE, 2018, 13, e0201671.	1.1	5
18	An Alternative Approach to Investigate Biofilm in Medical Devices: A Feasibility Study. International Journal of Environmental Research and Public Health, 2017, 14, 1587.	1.2	17

Elena Veronesi

#	Article	IF	CITATIONS
19	Potency Biomarker Signature Genes from Multiparametric Osteogenesis Assays: Will cGMP Human Bone Marrow Mesenchymal Stromal Cells Make Bone?. PLoS ONE, 2016, 11, e0163629.	1.1	24
20	Mesenchymal Progenitors Expressing <scp>TRAIL</scp> Induce Apoptosis in Sarcomas. Stem Cells, 2015, 33, 859-869.	1.4	46
21	Mesenchymal Progenitors Aging Highlights a miR-196 Switch Targeting HOXB7 as Master Regulator of Proliferation and Osteogenesis. Stem Cells, 2015, 33, 939-950.	1.4	56
22	Transportation Conditions for Prompt Use of <i>Ex Vivo</i> Expanded and Freshly Harvested Clinical-Grade Bone Marrow Mesenchymal Stromal/Stem Cells for Bone Regeneration. Tissue Engineering - Part C: Methods, 2014, 20, 239-251.	1.1	39
23	cGMP-Compliant Transportation Conditions for a Prompt Therapeutic Use of Marrow Mesenchymal Stromal/Stem Cells. Methods in Molecular Biology, 2014, 1283, 109-122.	0.4	3
24	Adipose stromal/stem cells assist fat transplantation reducing necrosis and increasing graft performance. Apoptosis: an International Journal on Programmed Cell Death, 2013, 18, 1274-1289.	2.2	56
25	Delayed Marrow Infusion in Mice Enhances Hematopoietic and Osteopoietic Engraftment by Facilitating Transient Expansion of the Osteoblastic Niche. Biology of Blood and Marrow Transplantation, 2013, 19, 1566-1573.	2.0	6
26	Transplanted Murine Long-term Repopulating Hematopoietic Cells Can Differentiate to Osteoblasts in the Marrow Stem Cell Niche. Molecular Therapy, 2013, 21, 1224-1231.	3.7	14
27	Isolation, Characterization, and Transduction of Endometrial Decidual Tissue Multipotent Mesenchymal Stromal/Stem Cells from Menstrual Blood. BioMed Research International, 2013, 2013, 1-14.	0.9	80
28	Transplanted bone marrow mononuclear cells and MSCs impart clinical benefit to children with osteogenesis imperfecta through different mechanisms. Blood, 2012, 120, 1933-1941.	0.6	118
29	MSC and Tumors: Homing, Differentiation, and Secretion Influence Therapeutic Potential. Advances in Biochemical Engineering/Biotechnology, 2012, 130, 209-266.	0.6	44
30	Understanding tumor-stroma interplays for targeted therapies by armed mesenchymal stromal progenitors: the Mesenkillers. American Journal of Cancer Research, 2011, 1, 787-805.	1.4	23
31	Osteopoietic engraftment after bone marrow transplantation: Effect of inbred strain of mice. Experimental Hematology, 2010, 38, 836-844.	0.2	6
32	GMP-manufactured density gradient media for optimized mesenchymal stromal/stem cell isolation and expansion. Cytotherapy, 2010, 12, 466-477.	0.3	59
33	Adipose-Derived Mesenchymal Stem Cells as Stable Source of Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Delivery for Cancer Therapy. Cancer Research, 2010, 70, 3718-3729.	0.4	226
34	Restoration and reversible expansion of the osteoblastic hematopoietic stem cell niche after marrow radioablation. Blood, 2009, 114, 2333-2343.	0.6	178